论文部分内容阅读
近10年来,肝硬化并原发性细菌性腹膜炎(SBP)的病理机理、预防和治疗有很大进展。资料显示头孢氨噻肟(cefotaxime)是治疗 SBP 最适当的早期应用的抗生素。因为头孢氨噻肟治疗效果好,没有肾毒性且二重感染的危险性低。本研究目的是确定肝硬化并发 SBP 的病人感染消退的标准和生存率。病人和方法 SBP 诊断标准:①腹水中多形核白细胞计数>250/mm~3;②排除继发感染。SBP 的诊断一旦确立,立即应用头孢氨噻肟治疗,剂量依照治疗期的肾功能而决定:在血清肌酐<1.5mg/d1、1.5～2.0mg/d1、2.0～2.5mg/d1
The past 10 years, cirrhosis and primary bacterial peritonitis (SBP) pathology, prevention and treatment of great progress. Data show that cefotaxime (cefotaxime) is the most appropriate early treatment of SBP antibiotics. Because cefotaxime treatment effect is good, there is no nephrotoxicity and the risk of double infection is low. The purpose of this study was to determine criteria and survival rates for regression of patients with cirrhosis complicated with SBP. Patients and methods SBP diagnostic criteria: ① ascites polymorphonuclear leukocyte count> 250 / mm ~ 3; ② exclude secondary infection. Once the diagnosis of SBP established immediately cefotaxime treatment, the dose according to the treatment of renal function and decide: serum creatinine <1.5mg / d1, 1.5 ~ 2.0mg / d1, 2.0 ~ 2.5mg / d1